Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$25.99 - $33.85 $46,106 - $60,049
1,774 New
1,774 $47,000
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $28 - $35
1 Added 6.25%
17 $1,000
Q2 2022

Aug 08, 2022

SELL
$25.33 - $34.25 $5,800 - $7,843
-229 Reduced 93.47%
16 $0
Q1 2022

May 10, 2022

BUY
$28.51 - $32.9 $6,984 - $8,060
245 New
245 $8,000
Q4 2021

Feb 11, 2022

SELL
$26.37 - $34.22 $7,700 - $9,992
-292 Closed
0 $0
Q3 2021

Nov 08, 2021

BUY
$23.54 - $31.39 $776 - $1,035
33 Added 12.74%
292 $8,000
Q2 2021

Aug 09, 2021

SELL
$26.72 - $33.19 $44,355 - $55,095
-1,660 Reduced 86.5%
259 $8,000
Q1 2021

Apr 28, 2021

BUY
$24.15 - $31.45 $46,343 - $60,352
1,919 New
1,919 $50,000
Q4 2020

Feb 09, 2021

SELL
$17.7 - $25.81 $87,544 - $127,656
-4,946 Closed
0 $0
Q3 2020

Nov 02, 2020

BUY
$20.2 - $25.05 $99,909 - $123,897
4,946 New
4,946 $102,000
Q2 2019

Aug 05, 2019

SELL
$29.96 - $38.87 $24,537 - $31,834
-819 Closed
0 $0
Q1 2019

Apr 16, 2019

SELL
$32.77 - $41.99 $1,998 - $2,561
-61 Reduced 6.93%
819 $28,000
Q4 2018

Jan 17, 2019

BUY
$30.84 - $49.51 $22,698 - $36,439
736 Added 511.11%
880 $30,000
Q3 2018

Nov 02, 2018

SELL
$42.7 - $56.55 $4,099 - $5,428
-96 Reduced 40.0%
144 $0
Q2 2018

Jul 24, 2018

SELL
$44.1 - $59.85 $41,983 - $56,977
-952 Reduced 79.87%
240 $0
Q1 2018

May 03, 2018

SELL
$37.15 - $46.9 $49,372 - $62,330
-1,329 Reduced 52.72%
1,192 $55,000
Q4 2017

Feb 02, 2018

BUY
$36.4 - $42.6 $9,063 - $10,607
249 Added 10.96%
2,521 $100,000
Q3 2017

Oct 20, 2017

BUY
$36.75 - $49.65 $83,496 - $112,804
2,272
2,272 $91,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.14B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.